Hence, the development of pharmacological inhibitors targeting human ATGL in WAT may be a useful strategy to combat obesity and obesity related disorders such as IR and NAFLD. This evidence concerns the gene PNPLA2 and obesity due to melanocortin 4 receptor deficiency.